MPL
Thrombopoietin receptor
As of the edition of 20 October 2026, MPL (thrombopoietin receptor, UniProt P40238) has 6 drugs tested at it and 11 companies on the list, 0 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P40238
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Blood and lymph; Immune system; Cancer; Digestive system; Infections; Inherited and neonatal; Heart and blood vessels; Skin and connective tissue
- Registered trials of its drugs
- 339
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Eltrombopag | Marketed | Phase 4 | Ended 2025 |
| Romiplostim | Marketed | Phase 4 | Ends 2028 |
| Avatrombopag | Marketed | Phase 4 | Ends 2032 |
| Hetrombopag olamine | Active | Phase 4 | none listed |
| Rafutrombopag | Stopped | Phase 4 | none listed |
| Lusutrombopag | Marketed | Phase 4 | Ends 2030 |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 6 |
| Engaged | 3 |
| Undetermined | 2 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Shionogi | Route B |
| Swedish Orphan Biovitrum | Route B |
The other 8 companies at MPL
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at MPL, ranked, with the facts behind eachRequest access. Nothing is shown until you do.